CLAIMS

1. Use of an anti-human tau antibody in the manufacture of a medicament for the treatment of Alzheimer's disease in a human subject in need thereof, wherein the medicament is to be administered intravenously to the human subject at a fixed dose of 2000 mg of the anti-human tau antibody once every four weeks, and wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:
   (a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:
      VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;
      VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and
      VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and
   (b) the VL comprises VL-CDRs, wherein:
      VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;
      VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and
      VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21.

2. The use of claim 1, wherein the VH consists of SEQ ID NO:12 and the VL consists of SEQ ID NO:13.

3. The use of claim 1 or claim 2, wherein the anti-human tau antibody comprises a heavy chain and a light chain, wherein the heavy chain consists of SEQ ID NO:14 and the light chain consists of SEQ ID NO:15.

4. An anti-human tau antibody at a fixed dose of 2000 mg for use in the treatment of Alzheimer's disease, wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:
   (a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:
      VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;
      VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and
      VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and

(b) the VL comprises VL-CDRs, wherein:

VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;

VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and

VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21.